Business Context and Reporting Period
Neurosense Therapeutics Ltd. filed a Form 6-K on September 4, 2025, reporting additional clinical data from its Phase 2b PARADIGM Study for the treatment of Amyotrophic Lateral Sclerosis (ALS). The data focuses on the largest study site in Israel, which enrolled 44 patients (approximately two-thirds of the total study population) and offers the most mature survival dataset due to an earlier enrollment start date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a clinical data update and does not contain financial statements.
Material Changes and Clinical Results
The report highlights a substantial difference in survival rates between the treatment arm (PrimeC) and the placebo arm at the Israeli study site:
- PrimeC Survival: 50% (15 of 30 participants) remain alive.
- Placebo Survival: Approximately 7% (1 of 14 participants) remain alive.
- Statistical Significance: The results represent a more than seven-fold survival advantage for PrimeC, achieving statistical significance (p=0.007, Fisher's exact test).
- Ventilation Status: Among survivors, 12 PrimeC participants remain ventilation-free compared to only 1 placebo participant.
Outlook, Management Commentary, and Risks
Management states that these results highlight the potential of PrimeC to meaningfully extend survival in ALS, a disease with urgent unmet needs. The Company continues to generate and analyze long-term clinical data to support regulatory submissions, including with Health Canada, as part of its global development and commercialization strategy. No specific financial risks or contingencies were detailed in this text.
Key Facts for Investor Verification
- Verify the total enrollment and survival data across all study sites, as this report covers only the Israeli site (44 patients).
- Confirm the timeline and status of regulatory submissions to Health Canada and other global agencies.
- Assess the company's cash runway and capital requirements to support continued development and commercialization efforts, as no financial data was provided in this filing.
- Review the full statistical analysis of the Phase 2b PARADIGM Study to understand the broader context of the p=0.007 significance level.